SCHEMBL3080463

SCHEMBL3080463

CCN(C(=O)C(CCCc1ccc(F)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.43
TPSAB1 Q15661 3/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 2/20 0.39
SLC16A3 O15427 1/20 0.38
F2 P00734 2/20 0.38
TBXAS1 P24557 1/20 0.38
MAPK14 Q16539 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
PTGER3 P43115 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093756 0.93 LARS1 (0.46) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3093369 0.92 LARS1 (0.44) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3093531 0.90 ALDH1A1 (0.51) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3086148 0.89 LARS1 (0.46) LARS1LMNAKMT2AMEN1F2
SCHEMBL3090337 0.88 POLB (0.44) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3100295 0.87 LARS1 (0.47) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3093370 0.86 LARS1 (0.45) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3089594 0.86 LARS1 (0.47) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3096411 0.86 LARS1 (0.45) LARS1TPSAB1LMNAKMT2AALDH1A1
SCHEMBL3100686 0.85 TBXAS1 (0.55) LARS1LMNATBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885TPSAB1 1070/4885LMNA 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.